Appointment of Independent Non-Executive Director
ImmuPharma PLC announced the immediate appointment of Ketan Patel as an independent Non-Executive Director to its board. Patel brings extensive expertise in financial markets, with a focus on the UK healthcare and life science sectors, accumulated from his experience as an analyst and Fund Manager at JP Morgan, Insight Investment and EdenTree Investment Management. Patel, aged 52, currently holds directorships at Global Asset and Property Management Limited, Whitefriars Property and Asset Management Limited, and Albion House Farringdon Exchange Management Limited. He previously held no directorships or partnerships within the last five years. Patel holds no shares in the Company.
Select text to share a quote on X · sign in to keep highlights & notes in your IMM notes
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. The appointment is with immediate effect.
Ketan is an experienced investment professional and brings extensive expertise in financial markets with a focus in the UK healthcare and life science sectors. He has been a long-term investor in UK markets, as an analyst and Fund Manager, running institutional, retail and charity mandates. Ketan started his career at JP Morgan, before moving to Insight Investment where he was a global Pharmaceutical and Healthcare analyst and spent over 20 years at EdenTree Investment Management where he was responsible for UK equity and global equity income strategies delivering consistent upper quartile performance.
Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes,
Ketan is a CFA Charterholder. He also holds an MSc Economic History, from London School of Economics, MSc Geography from King's College London and BA (Hons) History and Geography from Queen Mary University, London.
Tim McCarthy, Chief Executive Officer of ImmuPharma, said:
"We are extremely pleased to welcome Ketan to our Board. His extensive expertise in the global pharmaceutical and life science sectors and strong investment acumen will be invaluable to ImmuPharma.
Importantly, Ketan's appointment, at this time, brings a unique perspective to the Board, as we concentrate on future strategic partnerships and commercial deals across our product portfolio and in particular, our lead auto-immune platform technology, P140. In addition, Ketan's investment management experience will greatly assist us in expanding our institutional shareholder base."
Ketan Patel, commented:
"After nearly three decades of investing in mid and small cap UK companies with a focus on healthcare and life science, I am delighted to be joining the ImmuPharma team at this pivotal stage of their journey and look forward to contributing to the future success of the business."
Additional information:
Ketan Ratna Kanji Patel, aged 52, holds or has previously held the following directorships:
| C urrent directorships and/or partnerships | Former directorships and/or partnerships (within the last five years): |
| Global Asset and Property Management Limited Whitefriars Property and Asset Management Limited Albion House Farringdon Exchange Management Limited | None |
Ketan Patel holds no shares in the Company.
Save for the information above, there are no further disclosures to be made in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in respect of the appointment.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.